-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ATA-2271 in Malignant Pleural Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATA-2271 in Malignant Pleural Mesothelioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATA-2271 in Malignant Pleural Mesothelioma Drug Details: ATA-2271 is under development...
-
Product Insights
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Drugs In Development, 2023
Global Markets Direct’s, ‘End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drugs In Development, 2023’, provides an overview of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Thrombosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Thrombosis - Drugs In Development, 2023’, provides an overview of the Thrombosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thrombosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Kidney Disease (Chronic Renal Failure) - Drugs In Development, 2023’, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (Curcumin + Doxorubicin) in Colon Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Curcumin + Doxorubicin) in Colon Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Curcumin + Doxorubicin) in Colon Cancer Drug Details: Imx-110 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Gruticibart in End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gruticibart in End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gruticibart in End-Stage Kidney Disease...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mipasetamab Uzoptirine in Liposarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mipasetamab Uzoptirine in Liposarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Mipasetamab Uzoptirine in Liposarcoma Drug Details:ADCT-601(BGB-601) is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AB-023
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AB-023 Drug Details AB-023 is under development for the treatment of cardiovascular disease, thrombosis,...